Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care

• Status: Not yet recruiting
• Trial end date: 2022-08-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to describe the safety and efficacy outcomes of a cohort of ICU patients with severe COVID-19 respiratory disease treated with therapeutic dose Apixaban for COVID-19 at a tertiary public health care setting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Scotmann Pharmaceuticals
• Collaborator: Rawalpindi Medical College
• Treatments: Apixaban

Criteria

Inclusion Criteria:

• Adult (≥18 years of age)

• All admitted patients with severe or critical COVID-19

• Confirmed diagnosis of COVID-19 through RT-PCR (attach report) and/or HRCT Chest

• Patients at high risk of coagulopathy demonstrating signs of micro-thrombi induced organ dysfunction or strongly suspected macro thromboembolism

Exclusion Criteria:

• High risk of bleeding as judged by treating physicians

• Contra-indication to therapeutic anti coagulation

• Platelets < 50,000 (attach report)

• INR >1.5

• Evidence of current or recent bleeding